Targeting CV risk factors with GLP-1 RAs in people with obesity

Professor Michael Lincoff shares with us a discussion occurred during the EASD 2022 meeting, this was focusing on the modification of cardiovascular risk in patients with obesity with the GLP-1 receptor agonists.

Once weekly insulin: The ONWARDS 2 study

Professor Tina Vilsbøll chaired a very interesting session looking into once weekly insulin.

Is HFpEF hiding in your practice? Key messages of the DELIVER study: Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

We asked Professor Silvio Inzucchi about the key messages of the DELIVER study, he talked about this topic at the recent EASD 2022.

Semaglutide 2.4 mg reduces the 10-year type 2 diabetes risk in people with overweight or obesity

Professor Timothy Garvey, Director of Diabetes Research Center at University of Alabama presented new data from the STEP trial program at this year EASD Congress in Stockholm.

Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg

Domenica Rubino, Director of Washington Center for Weight Management & Research at Arlington, Virginia, USA, held a very interesting lecture about weight control at the recent EASD 2022 Congress.

Let’s talk about CGM evidence: Using basal insulins in T1D in daily life and when exercising

Continuous glucose monitoring gives us the opportunity to better analyze diabetes. The new insights help us to improve the therapy of our patients in the active daily life and even during physical exercise. Dr. Othmar Moser held two lectures about this topic the recent EASD 2022 congress.

Effect of liraglutide on muscle fat infiltration in adults with overweight or obesity

Professor Ambarish Pandey presented the results a randomised clinical trial about the effect of liraglutide on muscle fat infiltration in overweight or obesity adults at the recent EASD 2022 Congress. We asked him about the result.

Associations of hypoglycaemia and glycaemic variability with cardiac arrhythmias using a long-term monitoring approach in insulin-treated patients with type 2 diabetes

Dr. Andreas Andersen speaks about the data was presented in the EASD 2021.

The role of SGLT2 inhibitors in the treatment of diabetes with cardiovascular disease

The current issues in Hypoglycaemia

Prof. Brian Frier speak about the latest findings on the treatment of the disease.

Current guidelines on diabetes management

Prof. Christoph Wanner speaks about the latest guidelines and findings on treatment and comprehensive care for diabetes.

Accumulated CV data from SGLT2i outcomes trials

The dawn of CV risk reduction in type 2 diabetes: 5 years of SGLT2i CV outcome trials.

Summary of clinical and scientific topics discussed at EASD 2020 congress

The most important clinical and scientific findigs presented at the EASD 2020 Virtual Congress are summed up by Professor Stefano Del Prato.

Remission of type 2 diabetes with return of insulin secretory function restores normal pancreas morphology

The size and shape of the pancreas can be restored in individuals with type 2 diabetes who achieve remission as a result of an intensive weight loss and weight loss maintenance programme, shows a new analysis from the landmark DiRECT trial.

Effects of empagliflozin on physical activity and compensatory appetite responses in people with type 2 diabetes: the SEESAW trial

https://www.easd.org/virtualmeeting/home.html#!resources/effects-of-empagliflozin-diet-or-both-on-physical-activity-and-sedentary-behaviour-in-people-with-type-2-diabetes-analyses-from-the-seesaw-trial-33e5cd8a-0212-4173-ab31-02bd789ec795

Highlights of the 2019 EASD Congress

David R. Matthews, President of EASD explains the EASD statement on the new guidelines and summarize the highlights of the congress.

Medical Devices in Diabetes

Will SGLT2-inhibitors change the landscape?

Innate immunity in pancreatic islet inflammation

The artificial beta cell. When will the dream become reality?

Observational study of insulin pump treatment

The evidence for metformin is unclear?

The ORIGIN Study And Legacy Effects

EMPA-REG OUTCOME - a long-term, outcom study of empagliflozin in pateints with T2D at high CV risk

Principal investigator presenting the results of EMPA-REG OUTCOME trial

Joint Statement on Diabetes Self-Management Education

Joint Statement on Diabetes Self-Management Education

Joint Statement on Diabetes Self-Management Education

50 years of clinical research in diabetes

50 years in treatment of diabetes complications

50 years of diabetes treatment

75 years with diabetes – a patient’s perspective